Methods for Integration of Pharmacokinetic and Phenotypic Information in the Treatment of Infection with Human Immunodeficiency Virus

Acosta, Edward P.; King, Jennifer R.
February 2003
Clinical Infectious Diseases;2/1/2003, Vol. 36 Issue 3, p373
Academic Journal
Interest in monitoring antiretroviral drug concentrations in human immunodeficiency virus-infected patients has gained considerable momentum in recent years. We present a potential method for integrating pharmacokinetic and phenotypic information that will assist clinicians in choosing optimal treatment regimens for their patients and that will provide an approach for the interpretation of antiretroviral plasma drug concentrations.


Related Articles

  • Treatment of Human Immunodeficiency Virus 1--Infected Infants and Children with the Protease... Krogtad, Paul; Wiznia, Andrew; Luzuriaga, Katherine; Dankner, Wayne; Nielsen, Karin; Gersten, Merril; Kerr, Brad; Hendricks, Amy; Boczany, Barbara; Rosenberg, Martin; Jung, Denna; Spector, Stephen A.; Bryson, Yvonne // Clinical Infectious Diseases;5/1/1999, Vol. 28 Issue 5, p1109 

    Evaluates the safety, pharmacokinetics and antiretroviral activity of nelfinavir mesylate when administered to HIV-1 infected infants and children. Clinical characteristics; Laboratory findings; Pharmacokinetic analysis of subject; Toxic effects.

  • Effect of Gender and Race on the Pharmacokinetics of Pentamidine in HIV-Infected Patients. Conte, J.E.J.; Duncan, S.; McKenna, E.; Zurlinden, E. // Clinical Drug Investigation;1999, Vol. 17 Issue 4, p293 

    Objectives: We studied the effects of race and gender on the pharmacokinetics of intravenously administered pentamidine as women and minorities have been under-represented in earlier studies and the incidence of HIV and opportunistic infection is increasing in these groups. Patients and Methods:...

  • Stavudine: An Update of its Use in the Treatment of HIV Infection. Hurst, M.; Noble, S. // Drugs;Nov1999, Vol. 58 Issue 5, p919 

    Stavudine is a thymidine nucleoside analogue which is phosphorylated intracellularly to an active metabolite, stavudine 5′-triphosphate. This metabolite inhibits HIV replication, either by competing with thymidine 5′-triphosphate for incorporation into viral DNA by reverse...

  • Clinical pharmacokinetics of lamivudine. Johnson, M.A.; Moore, K.H.P.; Yuen, G.J.; Bye, A.; Pakes, G.E.; Moore, K H // Clinical Pharmacokinetics;1999, Vol. 36 Issue 1, p41 

    Lamivudine (3TC), the negative enantiomer of 2′-deoxy-3′-thiacytidine, is a dideoxynucleoside analogue used in combination with other agents in the treatment of human immunodeficiency virus type 1 (HIV-1) infection and as monotherapy in the treatment of hepatitis B virus (HBV)...

  • Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. López-Cortés, L.F.; Ruiz-Valderas, R.; Viciana, P.; Alarcón-González, A.; Gómez-Mateos, J.; León-Jimenez, E.; Sarasanacenta, M.; López-Pua, Y.; Pachón, J.; López-Cortés, Luis F; Ruiz-Valderas, Rosa; Viciana, Pompeyo; Alarcón-González, Aristides; Gómez-Mateos, Jesús; León-Jimenez, Eva; Sarasanacenta, Maria; López-Pua, Yolanda; Pachón, Jerónimo // Clinical Pharmacokinetics;Jul2002, Vol. 41 Issue 9, p681 

    Objective: To evaluate the pharmacokinetic interactions between efavirenz and rifampicin (rifampin) in patients with HIV infection and tuberculosis.Design: Nonblind, randomised, pharmacokinetic study.Patients: 24 patients (21 male, 3 female; mean age 37...

  • Pharmacokinetics and Pharmacodynamics of Nelfinavir Administered Twice or Thrice Daily to Human Immunodeficiency Virus Type 1--Infected Children. Gatti, G.; Castelli-Gattinara, G.; Cruciani, M.; Bernardi, S.; De Pascalis, C.R.; Pontali, E.; Papa, L.; Miletich, F.; Bassetti, D. // Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1476 

    We studied the pharmacokinetics and pharmacodynamics of nelfinavir administered 2 or 3 times per day to human immunodeficiency virus type 1 (HIV-1)-infected children receiving highly active antiretroviral therapy containing nelfinavir. The geometric mean trough concentrations of nelfinavir for...

  • Clinical practice treatment of HIV infection in children. Brichard, Bénédicte; Van der Linden, Dimitri; Brichard, Bénédicte // European Journal of Pediatrics;Apr2009, Vol. 168 Issue 4, p387 

    Perinatal transmission remains the main cause of HIV infection in the pediatric population. Treatment of HIV-infected children has become less of a problem in resource-rich countries with a remarkable decrease of perinatal infections, resulting in an effective prevention of mother-to-child...

  • Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Barry, M.; Mulcahy, F.; Merry, C.; Gibbons, S.; Back, D. // Clinical Pharmacokinetics;1999, Vol. 36 Issue 4, p289 

    There are 3 groups of drugs available for the treatment of patients with HIV disease. These are the nucleoside reverse transcriptase inhibitors (‘nucleoside analogues’) [zidovudine, didanosine, zalcitabine, lamivudine and abacavir]; the non-nucleoside reverse transcriptase...

  • Tipranavir: A Review of its Use in the Management of HIV Infection. Orman, Jennifer S; Perry, Caroline M // Drugs;2008, Vol. 68 Issue 10, p1435 

    Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics